Results of large series of reduced-intensity regimens for hematologic malignancies.
| Series . | Disease . | Regimen . | NRM . | OS . | Favorable Prognostic Factors . |
|---|---|---|---|---|---|
| *At 1 year; †at 1.5 years; ‡at 2 years; §at 3 years. | |||||
| Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CR, complete remission; F, fludarabine; FC, fludarabine/cyclophosphamide; FM, fludarabine/melphalan GVHD, graft-versus-host disease; MCL, mantle cell leukemia; MDS, myelodysplastic syndromes; NRM, non-relapse mortality; OS, overall survival; TBI, total-body irradiation. | |||||
| Robinson et al21 | Hodgkin disease | Various | 24%* | 46%‡ | Chemosensitive disease |
| Anderlini et al22 | Hodgkin disease | FM/FC | 22%† | 61%† | FM |
| Kroger et al25 | Myeloma | FM | 18%* | 59%‡ | Chemosensitive disease and limited chronic GVHD |
| Maloney et al24 | Myeloma | 200 cGy TBI (auto/allo) | 15%* | 78%‡ | |
| Crawley et al26 | Myeloma | Various | 26%‡ | 40%§ | Early disease |
| Khouri et al30 | MCL | FC +/− rituximab | 15%‡ | 86%‡ | Rituximab |
| Maris et al31 | MCL | F+ 200 cGy TBI | 24%‡ | 65%‡ | Remission patients |
| Dreger et al32 | CLL | Various | 18%* | ||
| Sorror et al33 | CLL | F+ 200 cGy TBI | 22%‡ | 60%‡ | |
| Niederwieser et al34 | AML/MDS | F+ 200 cGy TBI | 19%‡ | 45%‡ (CR1) | |
| Sayer et al35 | AML/MDS | Various | 53% | 52%‡ (CR1) | Lower disease burden |
| Ho et al36 | MDS | FM+Campath | 5% Sibs* 21% MUDS* | 73%* | Alemtuzumab given for GVHD prophylaxis |
| Wong et al37 | AML/MDS | Various | 55% * | 44%* | Remission status most important prognostic factor |
| Series . | Disease . | Regimen . | NRM . | OS . | Favorable Prognostic Factors . |
|---|---|---|---|---|---|
| *At 1 year; †at 1.5 years; ‡at 2 years; §at 3 years. | |||||
| Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CR, complete remission; F, fludarabine; FC, fludarabine/cyclophosphamide; FM, fludarabine/melphalan GVHD, graft-versus-host disease; MCL, mantle cell leukemia; MDS, myelodysplastic syndromes; NRM, non-relapse mortality; OS, overall survival; TBI, total-body irradiation. | |||||
| Robinson et al21 | Hodgkin disease | Various | 24%* | 46%‡ | Chemosensitive disease |
| Anderlini et al22 | Hodgkin disease | FM/FC | 22%† | 61%† | FM |
| Kroger et al25 | Myeloma | FM | 18%* | 59%‡ | Chemosensitive disease and limited chronic GVHD |
| Maloney et al24 | Myeloma | 200 cGy TBI (auto/allo) | 15%* | 78%‡ | |
| Crawley et al26 | Myeloma | Various | 26%‡ | 40%§ | Early disease |
| Khouri et al30 | MCL | FC +/− rituximab | 15%‡ | 86%‡ | Rituximab |
| Maris et al31 | MCL | F+ 200 cGy TBI | 24%‡ | 65%‡ | Remission patients |
| Dreger et al32 | CLL | Various | 18%* | ||
| Sorror et al33 | CLL | F+ 200 cGy TBI | 22%‡ | 60%‡ | |
| Niederwieser et al34 | AML/MDS | F+ 200 cGy TBI | 19%‡ | 45%‡ (CR1) | |
| Sayer et al35 | AML/MDS | Various | 53% | 52%‡ (CR1) | Lower disease burden |
| Ho et al36 | MDS | FM+Campath | 5% Sibs* 21% MUDS* | 73%* | Alemtuzumab given for GVHD prophylaxis |
| Wong et al37 | AML/MDS | Various | 55% * | 44%* | Remission status most important prognostic factor |